PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. PHAXIAM Therapeutics S.A. - Ordinary Share market cap is $1.01M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. PHAXIAM Therapeutics S.A. - Ordinary Share 52 week high is $0.0001 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. PHAXIAM Therapeutics S.A. - Ordinary Share 52 week low is $0.0001 as of November 18, 2026.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. PHAXIAM Therapeutics S.A. - Ordinary Share 50-day moving average is $0.0001.